New ALS Drug Extends Survival in Groundbreaking Trial

A new treatment for ALS significantly extended patient survival and delayed the need for breathing support in a Phase 2 trial, offering rare evidence of disease modification.

AP-101 works by clearing toxic protein clumps that damage nerve cells in people with the fatal disease.